肺腺鳞癌的内科治疗  

Medical treatment of lung adenosquamous carcinoma

作　　者：郭翠艳[1] 聂立功[1] Guo Cuiyan;Nie Ligong(Department of Respiratory and Critical Care Medicine,Peking University First Hospital,Beijing 10034,China)

机构地区：[1]北京大学第一医院呼吸和危重症医学科,北京100034

出　　处：《中国综合临床》2022年第4期294-297,共4页Clinical Medicine of China

摘　　要：肺腺鳞癌是非小细胞肺癌中一种少见的病理类型。肺腺鳞癌恶性程度高,临床预后差。对于失去手术机会或术后复发转移的患者,内科治疗占有重要的地位。含铂为基础的化学治疗仍是内科治疗的基石。推荐对于晚期肺腺鳞癌患者常规行驱动基因检测,对于有敏感驱动基因的患者,靶向治疗在部分患者中有确切疗效。免疫检查点抑制剂相关标记物的研究提示肺腺鳞癌患者可能从免疫治疗中获益,但目前尚缺乏临床实践数据。Adenosquamous carcinoma of the lung is a rare pathological type of non-small cell lung cancer.Adenosquamous carcinoma of the lung has a high degree of malignancy and poor clinical prognosis.Medical treatment plays an important role in patients who have lost the opportunity of operation or have recurrence and metastasis after operation.Platinum based chemotherapy is still the cornerstone of medical treatment.It is recommended that routine driver gene testing should be performed for patients with advanced lung adenosquamous carcinoma.For patients with sensitive driver genes,targeted therapy has a definite effect in some patients.Studies on markers related to immune checkpoint inhibitors suggest that patients with lung adenocarcinoma may benefit from immunotherapy,but there is still a lack of clinical practice data.

关 键 词：肺腺鳞癌 内科治疗 靶向治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]